Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Adam Kibel, M.D.

Co-Author

This page shows the publications co-authored by Adam Kibel and Philip Kantoff.
Connection Strength

0.536
  1. Mechanisms responsible for reduced erythropoiesis during androgen deprivation therapy in men with prostate cancer. Am J Physiol Endocrinol Metab. 2018 12 01; 315(6):E1185-E1193.
    View in: PubMed
    Score: 0.051
  2. Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With Prostate Cancer. J Endocr Soc. 2018 May 01; 2(5):485-496.
    View in: PubMed
    Score: 0.049
  3. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade. Prostate Cancer Prostatic Dis. 2018 09; 21(3):364-372.
    View in: PubMed
    Score: 0.048
  4. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018 02; 55(2):307-317.e1.
    View in: PubMed
    Score: 0.047
  5. Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. PLoS One. 2017; 12(9):e0184166.
    View in: PubMed
    Score: 0.047
  6. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539.
    View in: PubMed
    Score: 0.046
  7. Neoadjuvant Enzalutamide Prior to Prostatectomy. Clin Cancer Res. 2017 May 01; 23(9):2169-2176.
    View in: PubMed
    Score: 0.044
  8. Constitutive expression of high levels of prostate-specific antigen in the absence of prostate carcinoma. Urology. 1996 Nov; 48(5):741-6.
    View in: PubMed
    Score: 0.044
  9. Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. JAMA Oncol. 2016 Jan; 2(1):85-93.
    View in: PubMed
    Score: 0.042
  10. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol. 2015 Dec; 22(6):8048-55.
    View in: PubMed
    Score: 0.042
  11. Contemporary nationwide patterns of self-reported prostate-specific antigen screening. JAMA Intern Med. 2014 Nov; 174(11):1839-41.
    View in: PubMed
    Score: 0.039
  12. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol. 2014 Jun 20; 32(18):1889-94.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.